Clinical Characteristics And Outcomes Of The Double Refractory Cll Sll Treatment resistance and toxicity are leading clinical challenges in cll. limited data exist on outcomes for patients exposed to both bruton tyrosine kinase inhibitors (btkis) and b cell lymphoma 2 inhibitors (bcl2is). This study aims to evaluate outcomes among double exposed and double refractory pts. methods: in this single institution, retrospective study, we used our institutional cll database to identify pts with a cll sll diagnosis who were previously treated with both ven and a cbtki.
Case 4 A Patient With Relapsed Refractory Cll Recent years have seen significant improvement in chronic lymphocytic leukemia (cll) management. targeting b cell lymphoma (bcl 2) and bruton’s kinase (btk) have become the main strategies to restrain cll activity. In this article, we attempt to define the "double refractory" patient as resistant to both bruton's tyrosine kinase inhibitors (btki) and venetoclax for which prognosis is poor and there remains no standard of care. Treatment options for double refractory cll has improved recently with the approval of the non covalent btk inhibitor (ncbtki) pirtobrutinib as well as the cd19 targeted chimeric antigen receptor t cell (car t cell) therapy lisocabtagene maraleucel (liso cel). We analyzed the characteristics and outcomes of 95 patients with chronic lymphocytic leukemia (cll) post bruton tyrosine kinase inhibitor (btki) and b cell lymphoma 2 inhibitor (bcl2i) failure.
Key Clinical Data In Relapsed Refractory Cll Treatment options for double refractory cll has improved recently with the approval of the non covalent btk inhibitor (ncbtki) pirtobrutinib as well as the cd19 targeted chimeric antigen receptor t cell (car t cell) therapy lisocabtagene maraleucel (liso cel). We analyzed the characteristics and outcomes of 95 patients with chronic lymphocytic leukemia (cll) post bruton tyrosine kinase inhibitor (btki) and b cell lymphoma 2 inhibitor (bcl2i) failure. Matthew davids, md, dana farber cancer institute, boston, ma, briefly discusses real world retrospective data on the clinical characteristics, treatment patterns and outcomes of patients with chronic lymphocytic leukemia (cll) and small lymphocytic lymphoma (sll) who are relapsed refractory (r r) following btk inhibitor and bcl2 inhibitor exposure. Key efficacy outcomes included progression free survival (pfs), overall survival (os), and overall response rate (orr). results: from 3942 retrieved articles, 12 publications covering 8 unique studies (4 clinical trials and 4 observational studies) were included. We analyzed the characteristics and outcomes of 95 patients with chronic lymphocytic leukemia (cll) post bruton tyrosine kinase inhibitor (btki) and b cell lymphoma 2 inhibitor (bcl2i) failure. to clearly distinguish sensitivity and resistance to the targeted treatment classes, we defined double ref …. Chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) is an indolent hematological malignancy, characterized by the clonal proliferation and accumulation of functionally incompetent b cells in the blood, bone marrow, lymph nodes and spleen. 1 cll and sll are considered to be the same disease with different manifestations.
Comments are closed.